PURPOSE: Alterations in the RAS-RAF-MAP2K (MEK)-MAPK signaling pathway are major drivers in colorectal carcinogenesis. In colorectal cancer, BRAF mutation is associated with microsatellite instability (MSI), and typically predicts inferior prognosis. We examined the effect of BRAF mutation on survival and treatment efficacy in patients with stage III colon cancer. METHODS: We assessed status of BRAF c.1799T>A (p.V600E) mutation and MSI in 506 stageIII colon cancer patients enrolled in a randomized adjuvant chemotherapy trial [5-fluorouracil and leucovorin (FU/LV) vs. irinotecan (CPT11), FU and LV (IFL); CALGB 89803]. Cox proportional hazards model was used to assess the prognostic role of BRAF mutation, adjusting for clinical features, adjuvant chemotherapy arm, and MSI status. RESULTS: Compared with 431 BRAF wild-type patients, 75 BRAF-mutated patients experienced significantly worse overall survival [OS; log-rank P = 0.015; multivariate HR = 1.66; 95% CI: 1.05-2.63]. By assessing combined status of BRAF and MSI, it seemed that BRAF-mutated MSS (microsatellite stable) tumor was an unfavorable subtype, whereas BRAF wild-type MSI-high tumor was a favorable subtype, and BRAF-mutated MSI-high tumor and BRAF wild-type MSS tumor were intermediate subtypes. Among patients with BRAF-mutated tumors, a nonsignificant trend toward improved OS was observed for IFL versus FU/LV arm (multivariate HR = 0.52; 95% CI: 0.25-1.10). Among patients with BRAF wild-type cancer, IFL conferred no suggestion of benefit beyond FU/LV alone (multivariate HR = 1.02; 95% CI: 0.72-1.46). CONCLUSIONS:BRAF mutation is associated with inferior survival in stage III colon cancer. Additional studies are necessary to assess whether there is any predictive role of BRAF mutation for irinotecan-based therapy.
RCT Entities:
PURPOSE: Alterations in the RAS-RAF-MAP2K (MEK)-MAPK signaling pathway are major drivers in colorectal carcinogenesis. In colorectal cancer, BRAF mutation is associated with microsatellite instability (MSI), and typically predicts inferior prognosis. We examined the effect of BRAF mutation on survival and treatment efficacy in patients with stage III colon cancer. METHODS: We assessed status of BRAF c.1799T>A (p.V600E) mutation and MSI in 506 stage III colon cancerpatients enrolled in a randomized adjuvant chemotherapy trial [5-fluorouracil and leucovorin (FU/LV) vs. irinotecan (CPT11), FU and LV (IFL); CALGB 89803]. Cox proportional hazards model was used to assess the prognostic role of BRAF mutation, adjusting for clinical features, adjuvant chemotherapy arm, and MSI status. RESULTS: Compared with 431 BRAF wild-type patients, 75 BRAF-mutated patients experienced significantly worse overall survival [OS; log-rank P = 0.015; multivariate HR = 1.66; 95% CI: 1.05-2.63]. By assessing combined status of BRAF and MSI, it seemed that BRAF-mutated MSS (microsatellite stable) tumor was an unfavorable subtype, whereas BRAF wild-type MSI-high tumor was a favorable subtype, and BRAF-mutated MSI-high tumor and BRAF wild-type MSS tumor were intermediate subtypes. Among patients with BRAF-mutated tumors, a nonsignificant trend toward improved OS was observed for IFL versus FU/LV arm (multivariate HR = 0.52; 95% CI: 0.25-1.10). Among patients with BRAF wild-type cancer, IFL conferred no suggestion of benefit beyond FU/LV alone (multivariate HR = 1.02; 95% CI: 0.72-1.46). CONCLUSIONS:BRAF mutation is associated with inferior survival in stage III colon cancer. Additional studies are necessary to assess whether there is any predictive role of BRAF mutation for irinotecan-based therapy.
Authors: A Fariña-Sarasqueta; G van Lijnschoten; E Moerland; G-J Creemers; V E P P Lemmens; H J T Rutten; A J C van den Brule Journal: Ann Oncol Date: 2010-05-25 Impact factor: 32.976
Authors: Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs Journal: Gut Date: 2008-10-02 Impact factor: 23.059
Authors: Shuji Ogino; Jeffrey A Meyerhardt; Natsumi Irahara; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531
Authors: Ludovic Barault; Céline Charon-Barra; Valérie Jooste; Mathilde Funes de la Vega; Laurent Martin; Patrick Roignot; Patrick Rat; Anne-Marie Bouvier; Pierre Laurent-Puig; Jean Faivre; Caroline Chapusot; Francoise Piard Journal: Cancer Res Date: 2008-10-15 Impact factor: 12.701
Authors: Dallas R English; Joanne P Young; Julie A Simpson; Mark A Jenkins; Melissa C Southey; Michael D Walsh; Daniel D Buchanan; Melissa A Barker; Andrew M Haydon; Simon G Royce; Aedan Roberts; Susan Parry; John L Hopper; Jeremy J Jass; Graham G Giles Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07 Impact factor: 4.254
Authors: Amy J French; Daniel J Sargent; Lawrence J Burgart; Nathan R Foster; Brian F Kabat; Richard Goldberg; Lois Shepherd; Harold E Windschitl; Stephen N Thibodeau Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope Journal: Clin Cancer Res Date: 2014-03-31 Impact factor: 12.531
Authors: Kosuke Mima; Reiko Nishihara; Zhi Rong Qian; Yin Cao; Yasutaka Sukawa; Jonathan A Nowak; Juhong Yang; Ruoxu Dou; Yohei Masugi; Mingyang Song; Aleksandar D Kostic; Marios Giannakis; Susan Bullman; Danny A Milner; Hideo Baba; Edward L Giovannucci; Levi A Garraway; Gordon J Freeman; Glenn Dranoff; Wendy S Garrett; Curtis Huttenhower; Matthew Meyerson; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino Journal: Gut Date: 2015-08-26 Impact factor: 23.059
Authors: Xinwei Hua; Polly A Newcomb; Jessica Chubak; Rachel C Malen; Rebecca Ziebell; Aruna Kamineni; Lee-Ching Zhu; Melissa P Upton; Michelle A Wurscher; Sushma S Thomas; Hana Newman; Sheetal Hardikar; Andrea N Burnett-Hartman Journal: Cancer Causes Control Date: 2020-05-01 Impact factor: 2.506
Authors: Stacey Shiovitz; Monica M Bertagnolli; Lindsay A Renfro; Eunmi Nam; Nathan R Foster; Slavomir Dzieciatkowski; Yanxin Luo; Victoria Valinluck Lao; Raymond J Monnat; Mary J Emond; Nancy Maizels; Donna Niedzwiecki; Richard M Goldberg; Leonard B Saltz; Alan Venook; Robert S Warren; William M Grady Journal: Gastroenterology Date: 2014-05-21 Impact factor: 22.682
Authors: Julien Taieb; Karine Le Malicot; Qian Shi; Frédérique Penault-Llorca; Olivier Bouché; Josep Tabernero; Enrico Mini; Richard M Goldberg; Gunnar Folprecht; Jean Luc Van Laethem; Daniel J Sargent; Steven R Alberts; Jean Francois Emile; Pierre Laurent Puig; Frank A Sinicrope Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Frank A Sinicrope; Thomas C Smyrk; David Tougeron; Stephen N Thibodeau; Shalini Singh; Andrea Muranyi; Kandavel Shanmugam; Thomas M Grogan; Steven R Alberts; Qian Shi Journal: Cancer Date: 2013-05-08 Impact factor: 6.860
Authors: Van Morris; Michael J Overman; Zhi-Qin Jiang; Christopher Garrett; Shweta Agarwal; Cathy Eng; Bryan Kee; David Fogelman; Arvind Dasari; Robert Wolff; Dipen Maru; Scott Kopetz Journal: Clin Colorectal Cancer Date: 2014-06-23 Impact factor: 4.481
Authors: Oscar Murcia; Miriam Juárez; Eva Hernández-Illán; Cecilia Egoavil; Mar Giner-Calabuig; María Rodríguez-Soler; Rodrigo Jover Journal: World J Gastroenterol Date: 2016-04-07 Impact factor: 5.742
Authors: Nadine J McCleary; Kaori Sato; Reiko Nishihara; Kentaro Inamura; Teppei Morikawa; Xuehong Zhang; Kana Wu; Mai Yamauchi; Sun A Kim; Yasutaka Sukawa; Kosuke Mima; Zhi Rong Qian; Charles S Fuchs; Shuji Ogino; Jeffrey A Meyerhardt Journal: Clin Cancer Res Date: 2015-10-21 Impact factor: 12.531